139 related articles for article (PubMed ID: 8420593)
1. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.
Pigott TA; Hill JL; Grady TA; L'Heureux F; Bernstein S; Rubenstein CS; Murphy DL
Biol Psychiatry; 1993 Jan; 33(1):3-14. PubMed ID: 8420593
[TBL] [Abstract][Full Text] [Related]
2. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
[TBL] [Abstract][Full Text] [Related]
3. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
Goodman WK; McDougle CJ; Price LH; Barr LC; Hills OF; Caplik JF; Charney DS; Heninger GR
Biol Psychiatry; 1995 Aug; 38(3):138-49. PubMed ID: 7578657
[TBL] [Abstract][Full Text] [Related]
4. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
Zohar J; Mueller EA; Insel TR; Zohar-Kadouch RC; Murphy DL
Arch Gen Psychiatry; 1987 Nov; 44(11):946-51. PubMed ID: 3675134
[TBL] [Abstract][Full Text] [Related]
5. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
Broocks A; Pigott TA; Hill JL; Canter S; Grady TA; L'Heureux F; Murphy DL
Psychiatry Res; 1998 Jun; 79(1):11-20. PubMed ID: 9676822
[TBL] [Abstract][Full Text] [Related]
6. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
Zohar J; Insel TR
Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
[TBL] [Abstract][Full Text] [Related]
7. Low versus standard dose mCPP challenge in obsessive-compulsive patients.
Erzegovesi S; Martucci L; Henin M; Bellodi L
Neuropsychopharmacology; 2001 Jan; 24(1):31-6. PubMed ID: 11106873
[TBL] [Abstract][Full Text] [Related]
8. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
Hollander E; DeCaria C; Gully R; Nitescu A; Suckow RF; Gorman JM; Klein DF; Liebowitz MR
Psychiatry Res; 1991 Jan; 36(1):1-17. PubMed ID: 2017519
[TBL] [Abstract][Full Text] [Related]
9. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
[TBL] [Abstract][Full Text] [Related]
10. Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD).
Tucci MC; Dvorkin-Gheva A; Graham D; Amodeo S; Cheon P; Kirk A; Peel J; Taji L; Szechtman H
Psychopharmacology (Berl); 2013 May; 227(2):277-85. PubMed ID: 23354534
[TBL] [Abstract][Full Text] [Related]
11. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
Stein DJ; Van Heerden B; Wessels CJ; Van Kradenburg J; Warwick J; Wasserman HJ
Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug; 23(6):1079-99. PubMed ID: 10621951
[TBL] [Abstract][Full Text] [Related]
12. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects.
Kahn RS; Kalus O; Wetzler S; Cahn W; Asnis GM; van Praag HM
Psychiatry Res; 1990 Aug; 33(2):189-98. PubMed ID: 2243896
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder.
Kontis D; Boulougouris V; Papakosta VM; Kalogerakou S; Papadopoulos S; Poulopoulou C; Papadimitriou GN; Tsaltas E
Psychopharmacology (Berl); 2008 Nov; 200(4):597-610. PubMed ID: 18622751
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
de Leeuw AS; Westenberg HG
J Psychiatr Res; 2008 Sep; 42(11):894-901. PubMed ID: 18533183
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
Khanna S; John JP; Reddy LP
Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats.
Meert TF; Melis W; Aerts N; Clincke G
Behav Pharmacol; 1997 Aug; 8(4):353-63. PubMed ID: 9832994
[TBL] [Abstract][Full Text] [Related]
17. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.
Benkelfat C; Murphy DL; Zohar J; Hill JL; Grover G; Insel TR
Arch Gen Psychiatry; 1989 Jan; 46(1):23-8. PubMed ID: 2910220
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.
Anand A; Charney DS; Delgado PL; McDougle CJ; Heninger GR; Price LH
Am J Psychiatry; 1994 Nov; 151(11):1626-30. PubMed ID: 7943451
[TBL] [Abstract][Full Text] [Related]
19. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls.
Koreen AR; Lieberman JA; Alvir J; Chakos M
Neuropsychopharmacology; 1997 Jan; 16(1):61-8. PubMed ID: 8981389
[TBL] [Abstract][Full Text] [Related]
20. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder.
Goddard AW; Woods SW; Money R; Pande AC; Charney DS; Goodman WK; Heninger GR; Price LH
Psychiatry Res; 1999 Mar; 85(3):225-40. PubMed ID: 10333376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
